Bendamustine was first synthesized in the 1960s in East Germany as part of efforts to develop novel anticancer agents combining alkylating and antimetabolite properties. It was later studied extensively for its effectiveness against hematologic malignancies. The drug gained wider international recognition decades later and was approved by the U.S. Food and Drug Administration (FDA) in 2008 for the treatment of conditions such as chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma.
BRAND NAMES
Treanda – widely used in the United States
Bendeka – a newer formulation with a shorter infusion time
Belrapzo – another FDA-approved formulation
MECHANISM OF ACTION
Bendamustine works by damaging the DNA of cancer cells through alkylation, leading to cross-linking of DNA strands and preventing their replication. This disruption stops cell division and triggers programmed cell death (apoptosis). Additionally, it has antimetabolite-like properties that further interfere with DNA synthesis, making it effective against certain resistant cancer cells.
PHARMACOKINETICS
Absorption
Bendamustine is given intravenously, so it bypasses gastrointestinal absorption and enters the bloodstream directly, achieving full systemic availability immediately after infusion.
Distribution
Bendamustine is highly protein-bound in the blood (about 94–96 %), with only a small fraction (4–6 %) free to distribute into tissues. Its volume of distribution (20–25 L) indicates it mainly stays in the blood and extracellular fluid, with limited penetration into other tissues.
Metabolism
Bendamustine is primarily metabolized in the liver through hydrolysis to inactive metabolites, with a minor pathway involving the cytochrome P450 enzyme system (mainly CYP1A2) producing active metabolites.
Excretion
Bendamustine is excreted mainly through the feces, with a smaller portion eliminated via the kidneys in urine. Most of the drug is excreted as metabolites rather than unchanged drug.
PHARMACODYNAMICS
Bendamustine causes DNA damage in cancer cells, blocking their replication and triggering apoptosis. Its unique structure allows it to activate multiple cell death pathways, making it effective even against some chemotherapy-resistant tumors.
ADMINISTRATION
Bendamustine is administered intravenously by a healthcare professional, usually in a hospital or clinic setting, following a prescribed schedule based on the type of cancer and patient condition.
DOSAGE AND STRENGTH
Chronic lymphocytic leukemia (CLL): 100 mg/m² IV on days 1 and 2 of a 28-day cycle.
Indolent non-Hodgkin lymphoma: 120 mg/m² IV on days 1 and 2 of a 21-day cycle.
FOOD INTERACTIONS
Bendamustine has no known significant food interactions. It is given intravenously, so food intake does not affect its absorption or effectiveness.
DRUG INTERACTIONS
CYP1A2 inhibitors or inducers – drugs that affect this liver enzyme (e.g., fluvoxamine, rifampin) may alter bendamustine metabolism.
Other chemotherapy or immunosuppressive drugs – can increase risk of bone marrow suppression and infections.
Blood thinners (anticoagulants) – may increase the risk of bleeding when used concurrently.
CONTRAINDICATIONS
Severe allergic reactions to bendamustine or any of its components
Severe bone marrow suppression (low white blood cells, platelets, or red blood cells)
Pregnancy or breastfeeding, unless benefits outweigh risks, due to potential harm to the fetus or infant
Severe liver impairment, as metabolism may be significantly affected
SIDE EFFECTS
Fatigue, nausea, vomiting
Low blood cell counts (anemia, neutropenia, thrombocytopenia)
Fever, infections
Loss of appetite, diarrhea
Rash or mild skin reactions
TOXICITY
Bendamustine can cause toxicity mainly in the bone marrow, liver, and gastrointestinal system, leading to low blood counts, liver enzyme changes, nausea, and diarrhea. Severe effects may include infections, bleeding, or rare lung and infusion-related complications, so careful monitoring is required during treatment.
